Welcome, Frans and Ulrika. Thank you, Rikard. Thanks for having us. The scene is yours. Thank you, Rikard. We were going to present the Q2 interim report, which we have, and the earnings call today. Myself, Frans Venker, together with Ulrika Drotz, our CFO for Mentice. What we have today is, first of all, highlights in an overview, which I will present, the financial results by Ulrika. I have some concluding remarks, and then we have questions and answers, effectively what we see. What we see is overall key strategic measures that we implemented within the Mentice organization in a cautious market. We had net sales of SEK 63 million. What we saw is that the rolling 12 months net sales came out at SEK 261 million compared to SEK 281 million last year, of the last quarter, which is 7% lower than the previous quarter on a rolling 12 months. Order intake SEK 57.5 million. Also, rolling 12 months down 3% due to primarily weaker demand in APAC. That's also what we see is flat sales activities across EMEA and Americas. We see the order intake growing in EMEA and Americas, but APAC is where we see weaker demand. That is primarily also due to the lumpiness of the business, but also the development that we need to do with the medical device industry in order to capture that growth. Overall, we saw we had FDA-approved clearance, but also Brazilian clearance for our new release of Ankyras. That is really advancing our product offering across those markets. Also, what we see is that we are tracking towards the business case that we had, that is it when we implemented this also as an acquisition for Ankyras. We're tracking well in that. Also, our discussion with other companies, medical device industry companies, in order to sign up towards Ankyras and make them part of the ecosystems in order to drive flow diverters as also measurement of our pre-procedure planning. What we did this quarter was a strategic workforce alignment, which was initiated and announced in June of this year. It enables an estimated annual cost savings of approximately SEK 25 million. We have finalized and implemented this realignment now. That is in full execution. We expect also the first results already to come in also in Q3 of this. What we also did with this is a rights issue towards our shareholders, up to 10% of the shares. What is very good news is that there is a significantly high underwriting of these shares up to 66%, which means that there is strong support not only from our current shareholders, but also from our board, as I said, also our management team towards the strategy that we have implemented for growth. For that reason, we see it as a positive outlook. Healthcare systems business, as we also stated in the first quarter, is under review. We're looking for ways in order to drive a compelling value proposition also in this space that can be grown. We're doing this together with a team in order to see what kind of proposition actually can scale and how we can drive revenues for the next years for our hospital business. What we do see, of course, is that in the United States, a new bill was being released, the one big beautiful bill. That will also require us to be very specific on clinical evidence towards how we're going to drive solutions in the market and how they impact actually healthcare systems in, first of all, improving outcomes, but reducing also the cost base. That's what our simulation solutions are designed for. That clinical evidence will be part of that healthcare systems business review that we have implemented. In all, if you look at the business highlights, as I stated, we did a strategic workforce alignment that we initiated in June and already have implemented now, as I said, towards July, where the cost savings are coming in in Q3. We did this at quite a bit of speed in order to also make sure that those benefits are kicking in effectively quite soon. As stated also, this will help us with SEK 25 million on an annual basis from a cost base reduction standpoint. What we also did as part of that reorganization is that we consolidated our research and development, but also manufacturing activities for physical simulation to Denver, Colorado. That finalizes then also the vascular simulation and also Biomodex integration that we initiated a few years ago as part of acquisitions. That basically finalizes then the integration of that. Now, we have continued partnerships with 27 of the 30 largest medical device industry companies. They are really rewarded for our unique capabilities that we have towards our realism and realism that we offer as part of simulation towards devices that we implement for device companies and help physicians and care providers to provide patient care. Our strong commitment, what we see from those device companies, is helping us also towards the solid activity that we see in the remainder of the year for business going forward. We have done and are doing a strategic view of our healthcare systems market, as I initiated as well, and see for ways for sustainable, profitable growth for the years to come. Ankyras, I explained as well in Q2, what we saw is that we got clearance in Brazil and in the United States. That is helping us and will drive already profitable growth also for Q3 from an impact standpoint and helps us also to become part of the treatment base and the treatment market of our business. Finally, what we have done is for foreign exchange, we have hedged our dollar and euro for the remainder of this year. That will help us in order to compensate for fluctuations that are coming towards, basically, the Swedish krona. Finally, the rights issue, what I explained, to 10% of the share capital, which was announced, we expect this to be closed by September. As I stated also, this was quite positive and underwritten from the current shareholders, but also supported by the board and the management team of Mentice. In all, I'd say that will help us set up, I'd say, for future growth and profitable growth for the future to come. Maybe, Ulrika, if you could give a little bit more details towards the financials, please. Yes, thank you. I'm happy to. I will start with giving you some of the highlights for the second quarter of 2025. Net sales SEK 63 million. Compared to last year, yes, it's a decline organically of almost 33%. We need to remember that Q2 2024 was the so far all-time high record with sales over SEK 100 million. We are comparing with a very, very strong quarter from last year. Fair point. The order intake SEK 58 million. An organic decrease of SEK 40 million. Yes, there is an FX effect as well. When we look at, as Frans mentioned, the cautious medical device industry market and Americas being our biggest market, this actually affects the main impact comes from the Americas. Above all, also from APAC. From an EBITDA level, it's a minus result of SEK 8 million. We have in these minus 8 million costs taken for the strategic realignment that Frans mentioned. Adjusted, it's more or less a quarter where we reach a zero level of EBITDA. The order book has a growth of 4.3% if we compare with the second quarter of 2024, although there is an effect of FX with a reduction of minus 5%. Of the order book of SEK 112 million, the majority is planned for 2025, almost SEK 62 million. The operational cash flow, yes, it's affected by the result during Q2. It's minus with SEK 7 million. To comment a bit more about the cost and the effect of the strategic realignment, we've said many times in these earnings calls that we prefer to look at our business from a rolling 12 months perspective. The following graphs that you will see are based on a rolling 12 months perspective. The sales have had a negative development of - 7%. The EBITDA, what was, as I mentioned, affected with SEK 7.6 million, that was taken in the quarter. We estimate this to be the full cost for the strategic realignment. These costs are related to two separate areas. The biggest one is the workforce reduction, where the majority has happened in Sweden, but also in the U.S., France, and Spain. The second part is cost for consolidating the physical sim business from Paris and Stony Brook outside of New York to Denver, Colorado, which Frans also mentioned. We estimate the annual cost savings of these actions to be towards SEK 25 million. On a rolling 12 months perspective, looking at the order intake, we see a growth within the MDI, the medical device industry segment, which is our biggest segment. We see an increase in the Americas region and in the EMEA. This is unfortunately more than offset by the drop in APAC. The second quarter last year was a very strong quarter for APAC. This actually also affects these figures. Looking at HCS, the healthcare segment, there is a stable growth in all the regions. Looking at net sales, order intake becomes net sales. From a rolling 12 months perspective, we see a decline of the 7%. This is an effect of the very strong quarter in 2024 and the cautious market within the MDI segment, which affects the region Americas and APAC. We see for EMEA a stable growth both within the MDI segment and the healthcare segment. Finally, some comments about the recurring revenues, where we see an increase of 9% versus last year. We see the biggest increase in the software licenses, where we also see that we have 58% of these revenues coming from the region EMEA and 35% from the Americas. Very good. Thank you. I would like to make some concluding remarks. What we see is a cautious market overall due to macroeconomic factors, and that is affecting our business also. Still, I'd say we have a solid pipeline and interest from the medical device industry, despite the longer sales cycles that we currently see. New clearances for Ankyras, which we have for Brazil, but also the United States, give us on track, I'd say, for growth, but also contribution, profitable contribution in the third quarter. Positive effect on basically the reduced cost that we implemented for the strategic workforce and the realignment that we have done, as also the rights issue that we implemented and just announced also. It means a SEK 25 million on an annual basis from a cost-based reduction standpoint. The rights issue will generate approximately SEK 32 million, I'd say, and will contribute towards, first of all, our cash position, but also our investments that we're doing towards growth, both in R&D, but also in our sales organization in order to capture profitable growth for the years to come. I would like to state that it was underwritten well by currently the first, I'd say, the first and foremost, the shareholders in place, but also the board and the management team, which really underlines and supports the strategy that we have implemented for growth, not only in the medical device industry segment, but also for health system sales as also for robotics. Also, that latter part, the continuous long-term strategic focus on strengthening the business for our healthcare systems market is going to be critical. Despite laws that are basically implemented in the United States, we see ways in order to truly drive profitable growth there and make sure that we have a profitable future for the years to come. In that, what we see is that business highlights. It is what we see, as I stated, extended procurement cycles. We have done the workforce alignments, regulatory milestones, as also our approach that we're currently looking towards the image-guided interventional therapy space. With that, I would like to give it back to you, Rikard. Thank you. Thank you, Frans and Ulrika. I prepared a couple of questions. As a reminder, you can always ask questions via the chat on the web. My first question is, what are the main measures that you have taken in order to achieve close to break even adjusted EBITDA despite the sales development in the quarter? It is, I'd say, primarily two measures, but also, Ulrika, I'd say, correct me if I'm wrong. It's, first of all, the high gross margins that we basically have for our product portfolio, which is just over 90% this quarter. That is primarily due to, first of all, cost reduction measures that have been implemented within the cost of the portfolio, especially the hardware portfolio. It is also the mix where we are focusing more on software sales than only on the hardware components to it. That really supports us, as also a geographical mix will also play into this. When it comes towards the EBITDA levels, it is also related to very strict cost measurement. That's also what we have in place in order to make sure that we really look at, first of all, our discretionary spend, but actually our overall spend in order to make sure that we get the profitability where it needs to be. To your point, this really sets us up, I'd say, very well that if we get and when we get the revenues to grow and really grow, it will really offset and help us towards EBITDA levels for the years to come. That is the mission that we need to drive is profitable growth, but growth for Mentice. Okay, great. Have you taken any initiatives for the APAC market in order to return to rolling 12 months growth? Yes, because what we see is that, first of all, there's quite a bit of lumpiness, but indeed, I'd say it comes in chunks actually in time. What we have done as part of the strategic review that we implemented in Q2 and is still ongoing is that we're looking at the medical device industry market in order to see how we can grow this more effectively also in the APAC side. We do this globally, but we also would like to see this basically growth in APAC because the activity is there and we anticipate also that we can grow in this area. It is simply that is our commitment that we are driving at this moment. It's currently under strategic review and more on this basically the next months and quarters. Okay, great. Historically, Mentice has seen quite a lumpiness over quarters and will emphasize on the second half of the year. Is this a pattern that might repeat itself this year, or has the seasonal pattern changed? Of course, we hope that. What we do see is that we have solid activity both from the medical device industry side, with deals which were also already ongoing in Q1 and Q2, which we expect actually to close in the latter half of the year. I would say solid activity towards the medical device industry side. Hospital is basically continuing as expected. In that sense, we expect a decent, a good Q3 and Q4. Okay, great. Can you explain what is driving the rolling 12 months growth in sales in both EMEA and the Americas? Yeah, sure. It's related to our activities and our strong position that we have with the medical device industry businesses and the companies. What we do see is that we are connected and partnering with 27 of the top 30 medical device industry companies. What they really reward us and also tell us is that we are unique from a realism perspective. We have the ability to truly provide simulation solutions that help the medical device industry in order to teach, but also train their physicians to implement new devices. We are rewarded for that, I'd say, in our unique solutions that we provide. I'd say that is also driving the growth if it comes towards the European or EMEA perspective, but also the Americas. We saw our order intake also from a rolling 12 months. We saw it actually growing quite significantly, almost both almost double digits. That was unfortunately offset by what we saw in APAC. Especially in EMEA and Americas, that was doing well. Did I miss anything, Ulrika? No, I think you put it together nicely. Okay, great. Moving on forward to equity rise, how approximately will you use the proceeds that you will get in this? Yeah, so what we have done is a rights issue indeed, which was announced today. Our expectation is that we're going to get approximately SEK 32 million out of this. That will support three things. That is, first of all, the cash position that we have on hand. I'd say the second piece is related to investments, investments for growth opportunities that we see for the future to come. Those investments will go, first of all, into R&D and innovation in order to drive realism further that is required, especially for the healthcare market, where they, for example, would like to have patient-specific simulation, which means that you can navigate or simulate on a patient that is actually not simulated, but the real patient on the table, that you can do that in a virtual environment. That is what we would like to bring to market. Secondarily, it's also linked, as I stated, also towards clinical evidence and business proof points in order to sell our solutions in the market, but also with the right sales organization that we have done in place with the support structure. That is what we are driving of what we are doing with the proceedings. It will approximately be even a third, a third, a third with respect to what we get out of this. Okay, great. I'm moving on to some questions while we're looking forward a bit. Basically, first of all, what is like the main area where you aim to see cost reductions going forward given the announced programs? Cost reductions, I'd say, going forward, I'd say what we have actually implemented already is basically a reorganization. We have driven, I'd say, efficiency and effectiveness measures. We have consolidated, for example, our efforts into basically the physical simulation activities, which we're bringing over to Denver. We're really committed to this portfolio going forward, but in a more efficiency and effective way going forward. At this moment, I'd say we need to remain frugal from a cost-based perspective, but I don't see further cost reduction measures, I'd say, needed. Ulrika, anything you see where we need to do that? No, I think the measures that we have taken now are to support the strategy for the growth going forward. There are, as you said, cost reductions within the consolidation of the physical sim. Obviously, the majority of the cost reduction comes from workforce reductions, which have been done both in Sweden and the U.S., Spain, and France. Okay, good. How has the market received the new updated Ankyras products? What is your strategy for this going forward? Very good question. Actually, it's going quite well. It is according to our internal expectations also when we acquired Ankyras. Especially with the current approvals and clearances that we received in the United States, as also in Brazil, we see the uptake also coming along. It is tracking, I'd say, close towards what we anticipated from an uptake perspective. Currently, we are in discussions also with other device companies in order to see whether we can accelerate this growth. We really need this Ankyras product also in order to support our business if it comes towards pre-procedure planning and especially to get into treatment of the neurovascular domain. The link that we can provide and also to our virtual simulation, the combination of virtual simulation as also pre-procedure planning is a unique but also very powerful solution in order to grow in the healthcare space. We anticipate this to be a stepping stone not only for neurovascular but potentially for other clinical domains as well, where we would like to do similar measures in order to grow our business going forward. Okay, great. If we look on the, sorry, the healthcare segment, how is the strategy for that going forward? It is something which is currently under review. We have been, I'd say, in this market for quite a while, from my perspective, not growing fast enough. That is related to needing to create more clinical evidence on our outcomes, how it contributes towards cost reduction, as well as how it contributes towards clinical outcomes. That is what we're currently looking at with the team in order to see if we can create propositions that are easier to scale towards larger networks of delivery networks for healthcare in order to grow further there. That is our anticipated strategy, what we'll do. We will hear more in the second half of how we're going to do this. We're currently reviewing it. It is not in execution yet. We're reviewing the strategy as we speak. Okay, great. Lastly, can you please discuss a bit on how the new used budget rules and bills will affect your business going forward? Yeah, it's a very good question because there's a lot happening in the market, specifically also in North America, where there was a new business bill going through Congress, the one big beautiful bill. What you see is that, and also what you read from the news, is that it will have quite an impact in the future of patients who are going to be insured under Medicaid. That will probably also have an impact towards revenues of hospitals. It will have a negative impact on hospitals. Specifically, what we read is that, and what we see and anticipate is that for smaller hospitals, they will be more impacted. What it means for us is that our solutions are even more important, I'd say, first of all, to support clinical outcomes, but also cost reduction for hospitals, especially when it comes towards image-guided interventional therapy clinical procedures. We need to make sure that we have the clinical evidence, I'd say, supporting those outcomes so that we can show that our solutions help in order to with clinical treatment care. In that sense, it confirms our strategy that we are relevant as simulation and that we need to drive, I'd say, those solutions in order to improve outcome, create access to care, be there for care providers, and lowering cost. Okay, excellent. Frans, Ulrika, thank you for coming here to DNB Carnegie Bank. Thank you, everyone who has been watching. Thank you, Rikard, for having us.